By openly acknowledging that semaglutide depression and related concerns can occur, providers and patients can create proactive monitoring plans rather than being caught off guard
Weight regain risk during the transition Research consistently shows that approximately two-thirds of patients regain weight when they stop GLP-1 receptor agonist therapy
Functional heterogeneity expresses itself via differences in metabolism, oxygen supply, b-oxidation, amino acid metabolism, gluconeogenesis, glycolysis, ureagenesis, liponeogenesis, and bile acid and bilirubin secretion
It works by decreasing appetite and slowing down gastric emptying, which helps to reduce food intake
Our data also raise the possibility that WGD and/or the enhanced tolerance it confers to continued acquisition of AI, might have prognostic significance in melanoma